166 related articles for article (PubMed ID: 26679394)
1. Updates from guardian™: a comprehensive registration programme.
Ozelo MC
Eur J Haematol; 2015 Dec; 95 Suppl 81():22-9. PubMed ID: 26679394
[TBL] [Abstract][Full Text] [Related]
2. Long-term safety and efficacy of turoctocog alfa in prophylaxis and treatment of bleeding episodes in severe haemophilia A: Final results from the guardian 2 extension trial.
Lentz SR; Janic D; Kavakli K; Miljic P; Oldenburg J; C Ozelo M; Santagostino E; Suzuki T; Zupancic Šalek S; Korsholm L; Matytsina I; Tiede A
Haemophilia; 2018 Nov; 24(6):e391-e394. PubMed ID: 30402994
[TBL] [Abstract][Full Text] [Related]
3. Results from a large multinational clinical trial (guardian™3) using prophylactic treatment with turoctocog alfa in paediatric patients with severe haemophilia A: safety, efficacy and pharmacokinetics.
Kulkarni R; Karim FA; Glamocanin S; Janic D; Vdovin V; Ozelo M; Rageliene L; Carboni E; Laguna P; Dobaczewski G; Seremetis S; Lindblom A; Santagostino E
Haemophilia; 2013 Sep; 19(5):698-705. PubMed ID: 23651313
[TBL] [Abstract][Full Text] [Related]
4. Results from a large multinational clinical trial (guardian™1) using prophylactic treatment with turoctocog alfa in adolescent and adult patients with severe haemophilia A: safety and efficacy.
Lentz SR; Misgav M; Ozelo M; Salek SZ; Veljkovic D; Recht M; Cerqueira M; Tiede A; Brand B; Mancuso ME; Seremetis S; Lindblom A; Martinowitz U
Haemophilia; 2013 Sep; 19(5):691-7. PubMed ID: 23647704
[TBL] [Abstract][Full Text] [Related]
5. Impact of severe haemophilia A on patients' health status: results from the guardian(™) 1 clinical trial of turoctocog alfa (NovoEight(®) ).
Ozelo M; Chowdary P; Regnault A; Busk AK
Haemophilia; 2015 Jul; 21(4):451-7. PubMed ID: 25677761
[TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of turoctocog alfa in the prevention and treatment of bleeds in previously untreated paediatric patients with severe haemophilia A: Results from the guardian 4 multinational clinical trial.
Yaish H; Matsushita T; Belhani M; Jiménez-Yuste V; Kavakli K; Korsholm L; Matytsina I; Philipp C; Reichwald K; Wu R
Haemophilia; 2020 Jan; 26(1):64-72. PubMed ID: 31816159
[TBL] [Abstract][Full Text] [Related]
7. Safety and efficacy of turoctocog alfa (NovoEight®) during surgery in patients with haemophilia A: results from the multinational guardian™ clinical trials.
Santagostino E; Lentz SR; Misgav M; Brand B; Chowdary P; Savic A; Kilinc Y; Amit Y; Amendola A; Solimeno LP; Saugstrup T; Matytsina I
Haemophilia; 2015 Jan; 21(1):34-40. PubMed ID: 25273984
[TBL] [Abstract][Full Text] [Related]
8. Zero incidence of factor VIII inhibitors and successful haemostatic response in previously factor VIII-treated patients with haemophilia A switching to turoctocog alfa in a noninterventional study.
Escuriola Ettingshausen C; Katsarou O; Kotnik BF; Borel Derlon A; Schwarz R; Ypma PF; Matytsina I; Dey S; Schutgens REG
Haemophilia; 2022 Jan; 28(1):46-54. PubMed ID: 34791736
[TBL] [Abstract][Full Text] [Related]
9. Turoctocog alfa pegol provides effective management for major and minor surgical procedures in patients across all age groups with severe haemophilia A: Full data set from the pathfinder 3 and 5 phase III trials.
Tosetto A; Neff A; Lentz SR; Santagostino E; Nemes L; Sathar J; Meijer K; Chowdary P; Shen C; Landorph A; Hampton K
Haemophilia; 2020 May; 26(3):450-458. PubMed ID: 32293786
[TBL] [Abstract][Full Text] [Related]
10. Long-term patterns of safety and efficacy of bleeding prophylaxis with turoctocog alfa (NovoEight(®) ) in previously treated patients with severe haemophilia A: interim results of the guardian(™) 2 extension trial.
Ozelo M; Misgav M; Abdul Karim F; Lentz SR; Martin-Salces M; Matytsina I; Saugstrup T; Santagostino E
Haemophilia; 2015 Sep; 21(5):e436-9. PubMed ID: 26058730
[No Abstract] [Full Text] [Related]
11. Turoctocog alfa (recombinant factor VIII). Manufacturing, characteristics and clinical trial results.
Tiede A; Klamroth R; Oldenburg J
Hamostaseologie; 2015; 35(4):364-71. PubMed ID: 26271775
[TBL] [Abstract][Full Text] [Related]
12. Interim results from a large multinational extension trial (guardian(™) 2) using turoctocog alfa for prophylaxis and treatment of bleeding in patients with severe haemophilia A.
Lentz SR; Cerqueira M; Janic D; Kempton C; Matytsina I; Misgav M; Oldenburg J; Ozelo M; Recht M; Rosholm A; Savic A; Suzuki T; Tiede A; Santagostino E
Haemophilia; 2016 Sep; 22(5):e445-9. PubMed ID: 27291066
[No Abstract] [Full Text] [Related]
13. Turoctocog alfa: an evidence-based review of its potential in the treatment of hemophilia A.
Takedani H; Hirose J
Drug Des Devel Ther; 2015; 9():1767-72. PubMed ID: 25848213
[TBL] [Abstract][Full Text] [Related]
14. Real-world long-term safety and effectiveness of turoctocog alfa in the treatment of haemophilia A in Japan: results from a multicentre, non-interventional, post-marketing study.
Nagao A; Deguchi A; Nogami K
Hematology; 2024 Dec; 29(1):2316540. PubMed ID: 38376107
[TBL] [Abstract][Full Text] [Related]
15. Safety and efficacy of a glycoPEGylated rFVIII (turoctocog alpha pegol, N8-GP) in paediatric patients with severe haemophilia A.
Meunier S; Alamelu J; Ehrenforth S; Hanabusa H; Abdul Karim F; Kavakli K; Khodaie M; Staber J; Stasyshyn O; Yee DL; Rageliene L
Thromb Haemost; 2017 Aug; 117(9):1705-1713. PubMed ID: 28692108
[TBL] [Abstract][Full Text] [Related]
16. Clinical evaluation of glycoPEGylated recombinant FVIII: Efficacy and safety in severe haemophilia A.
Giangrande P; Andreeva T; Chowdary P; Ehrenforth S; Hanabusa H; Leebeek FW; Lentz SR; Nemes L; Poulsen LH; Santagostino E; You CW; Clausen WH; Jönsson PG; Oldenburg J;
Thromb Haemost; 2017 Jan; 117(2):252-261. PubMed ID: 27904904
[TBL] [Abstract][Full Text] [Related]
17. Once-weekly prophylaxis with glycoPEGylated recombinant factor VIII (N8-GP) in severe haemophilia A: Safety and efficacy results from pathfinder 2 (randomized phase III trial).
Curry N; Albayrak C; Escobar M; Andre Holme P; Kearney S; Klamroth R; Misgav M; Négrier C; Wheeler A; Santagostino E; Shima M; Landorph A; Tønder SM; Lentz SR
Haemophilia; 2019 May; 25(3):373-381. PubMed ID: 30817066
[TBL] [Abstract][Full Text] [Related]
18. Safety and Efficacy of Turoctocog Alfa in the Prevention and Treatment of Bleeding Episodes in Previously Treated Patients from China with Severe Hemophilia A: Results from the Guardian 7 Trial.
Wu R; Sun J; Xu W; Hu Q; Li W; Xiao J; Yang F; Zeng X; Zeng Y; Zhou J; Matytsina I; Zhang S; Pluta M; Yang R
Ther Clin Risk Manag; 2020; 16():567-578. PubMed ID: 32606716
[TBL] [Abstract][Full Text] [Related]
19. Turoctocog alfa for the treatment of hemophilia a.
Vakil NH; Fujinami N; Martin-Stone S
Pharmacotherapy; 2014 Oct; 34(10):1091-101. PubMed ID: 25052207
[TBL] [Abstract][Full Text] [Related]
20. Turoctocog alfa for the treatment of hemophilia A.
Haddley K
Drugs Today (Barc); 2014 Feb; 50(2):121-31. PubMed ID: 24619589
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
